Literature DB >> 22057681

The expression of PCNA, c-erbB-2, p53, ER and PR as well as atypical hyperplasia in tissues nearby the breast cancer.

Zongliang Jia1, Wei Zhao, Lin Fan, Wei Sheng.   

Abstract

To examine the proper margin for breast conservative surgery in Chinese women population. 40 breast cancer specimens were collected and each sample was dissected into several groups: primary tumor group, 1 cm paracarcinoma, 2 cm paracarcinoma, 3 cm paracarcinoma and excessive 3 cm paracarcinoma groups. The immunohistochemistry staining was performed to measure the expression levels of proliferating cell nuclear antigen (PCNA), c-erbB-2, p53, estrogen receptor (ER) and progesterone receptor (PR). The gene expressions of PCNA, c-erbB-2, and p53 gradually decreased with the increased distance from primary tumor (P < 0.05). The 1 and 2 cm paracarcinoma group (no differences between the two, P > 0.05) showed higher risk factors (c-erbB-2, p53) than the 3 cm and excessive 3 cm paracarcinoma groups (P < 0.05). The expression of PCNA, ER, and PR showed no correlation with cancer progression (P > 0.05). Beyond the paracarcinoma 2 cm distance, the tissues showed significant decreases in tumor gene expression, which could represent the appropriate region for breast conservative surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057681     DOI: 10.1007/s10735-011-9371-1

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  13 in total

1.  Role of resection margins in patients treated with breast conservation surgery.

Authors:  Giorgio Zavagno; Elena Goldin; Roberto Mencarelli; Giovanni Capitanio; Paola Del Bianco; Renato Marconato; Simone Mocellin; Giorgia Marconato; Valentina Belardinelli; Francesca Marcon; Donato Nitti
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

2.  Breast conservation and negative margins: how much is enough?

Authors:  M Morrow
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

3.  c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue.

Authors:  A McCann; P A Johnston; P A Dervan; W J Gullick; D N Carney
Journal:  Ir J Med Sci       Date:  1989-06       Impact factor: 1.568

4.  A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker.

Authors:  Linda H Malkas; Brittney Shea Herbert; Waleed Abdel-Aziz; Lacey E Dobrolecki; Yang Liu; Beamon Agarwal; Derek Hoelz; Sunil Badve; Lauren Schnaper; Randy J Arnold; Yehia Mechref; Milos V Novotny; Patrick Loehrer; Robert J Goulet; Robert J Hickey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-11       Impact factor: 11.205

5.  p53 Isoforms: An Intracellular Microprocessor?

Authors:  Marie P Khoury; Jean-Christophe Bourdon
Journal:  Genes Cancer       Date:  2011-04

6.  C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.

Authors:  Takao Kato; Shingo Kameoka; Tsunehito Kimura; Toshio Nishikawa; Makio Kobayashi
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

Review 7.  The surgical margin status after breast-conserving surgery: discussion of an open issue.

Authors:  Alberto Luini; Joel Rososchansky; Giovanna Gatti; Stefano Zurrida; Pietro Caldarella; Giuseppe Viale; Gabriela Rosali dos Santos; Antonio Frasson
Journal:  Breast Cancer Res Treat       Date:  2009-01       Impact factor: 4.872

Review 8.  p53 in breast cancer: mutation and countermeasures.

Authors:  Sumit Kumar; Vijay Walia; Maria Ray; Randolph C Elble
Journal:  Front Biosci       Date:  2007-05-01

9.  Preoperative MRI marking technique for the planning of breast-conserving surgery.

Authors:  Norie Yamashiro; Mitsuhiro Tozaki; Tomoko Ogawa; Naoko Kawano; Takako Suzuki; Shinji Ozaki; Naomi Sakamoto; Satoko Abe; Eisuke Fukuma
Journal:  Breast Cancer       Date:  2009-02-10       Impact factor: 4.239

Review 10.  p53 and disease: when the guardian angel fails.

Authors:  J A Royds; B Iacopetta
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

View more
  7 in total

1.  Protein expression pattern of human MIER1 alpha, a novel estrogen receptor binding protein.

Authors:  Patti L McCarthy; Gary D Paterno; Laura L Gillespie
Journal:  J Mol Histol       Date:  2013-01-01       Impact factor: 2.611

2.  CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.

Authors:  Agnieszka Adamczyk; Joanna A Niemiec; Aleksandra Ambicka; Anna Mucha-Małecka; Jerzy Mituś; Janusz Ryś
Journal:  J Mol Histol       Date:  2013-07-09       Impact factor: 2.611

3.  cIAP2 expression and clinical significance in pigmented villonodular synovitis.

Authors:  Zhenyu Ding; Zhenlong Bai; Miao Zhang; Benben Sun; Yaohua He
Journal:  J Mol Histol       Date:  2021-02-18       Impact factor: 2.611

4.  Involvement of NF-κB and HSP70 signaling pathways in the apoptosis of MDA-MB-231 cells induced by a prenylated xanthone compound, α-mangostin, from Cratoxylum arborescens.

Authors:  Mohamed Yousif Ibrahim; Najihah Mohd Hashim; Syam Mohan; Mahmood Ameen Abdulla; Siddig Ibrahim Abdelwahab; Behnam Kamalidehghan; Mostafa Ghaderian; Firouzeh Dehghan; Landa Zeenelabdin Ali; Hamed Karimian; Maizatulakmal Yahayu; Gwendoline Cheng Lian Ee; Abdoreza Soleimani Farjam; Hapipah Mohd Ali
Journal:  Drug Des Devel Ther       Date:  2014-11-06       Impact factor: 4.162

5.  Downregulation of PDIA3 inhibits proliferation and invasion of human acute myeloid leukemia cells.

Authors:  Qidong Ye; Pan Fu; Jiaying Dou; Nina Wang
Journal:  Onco Targets Ther       Date:  2018-05-17       Impact factor: 4.147

6.  Ribophorin II promotes cell proliferation, migration, and invasion in esophageal cancer cells in vitro and in vivo.

Authors:  Yongshun Li; Changrong Huang; Qizhou Bai; Jun Yu
Journal:  Biosci Rep       Date:  2019-05-07       Impact factor: 3.840

7.  Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.

Authors:  Xiaomei Yang; Jing Zhao; Siliang Duan; Xiaoqiong Hou; Xi Li; Zixi Hu; Zhuoran Tang; Fengzhen Mo; Xiaoling Lu
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.